Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

"We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wri
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 SoundConnect , an ... Office 365 end users the key to turning ... system by adding voice enablement and hybrid audio ... Online, a communication tool that includes presence, instant ... voice, O365 becomes a comprehensive unified communications solution. ...
(Date:10/30/2014)... Whitehouse Laboratories has formally announced a ... and Package Test Capacity. Responding to growing demands from ... increase in environmental chamber storage space that will enable ... samples to be securely held on site at Whitehouse ... has already taken place with the recent completion of ...
(Date:10/30/2014)... -- A new report, commissioned by BioCrossroads and conducted ... look at Indiana,s capital market ... different time frames: 1993 to 2002 and 2003 to ... for investment growth.  The Life Science Innovation Capital ... in innovation dollars as well as an increase in ...
(Date:10/27/2014)... 2014 Ryan Carfley , Managing Partner ... sit down with Bryan Hamilton, the publisher of the Triangle ... talent in the Research Triangle region of North Carolina. , ... at the roundtable include the role of social media ... work/life balance and the unique role that Millennials play in ...
Breaking Biology Technology:SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... , , ... software for the analysis of RNA, DNA, proteins, and cells with the ... , , , , ... tool for RNA,DNA proteins and cells., , , ...
... , , ... , , , This Application ... apoptotic cell samples. Performance of two assays,for apoptosis detection is demonstrated ... cytometer. Histogram quality,of the low number of fluorescent cells counted with ...
... , , ... , , , ... become an essential tool in any,laboratory working on cell-based studies. ... also the determination of growth factor,and cytokine activity. Even more ...
Cached Biology Technology:2100 expert software , Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer 2Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 2Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 4Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 5Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 6Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 7Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 8Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 9Cell Proliferation and Viability Measurement 2Cell Proliferation and Viability Measurement 3Cell Proliferation and Viability Measurement 4
(Date:10/30/2014)... , Oct. 29, 2014  Securus ... criminal justice technology solutions for public safety, ... it has deployed exciting enhancements to its ... analytics to provide actionable intelligence and focused ... continues to drive technological innovation through identifying ...
(Date:10/29/2014)... is open for the Society of ... SIR 2015 is the one place where ... related health care professionals can come together ... and technologies being presented, discussed and tested. ... minimally invasive, image-guided medicine, SIR 2015 will ...
(Date:10/29/2014)... ceremony held in New York City on September 19, ... American Cancer Society Professor of Genome Sciences and Medicine ... Honorary Doctor of Philosophy of Tel Aviv University, was ... Science. , In addition to her honorary degree from ... the TAU School of Medicine, and for the past ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2
... and Technology (NIST) spent 75 days on the job ... dwelling" of the release, distribution and fate of particles ... DNA molecule. Particles ranging in size from 100 nanometers ... and electric stoves, hair dryers, power tools and candles ...
... Philadelphia, PA, -- MicroRNAs (miRNAs) that regulate processes including ... disease. They can be collected from routinely collected ... a number of factors can interfere with the accuracy ... today in the Journal of Molecular Diagnostics , ...
... for females to avoid unwanted male attention: choosing more attractive ... of the Royal Society B, the study is the ... attractive than themselves to reduce harassment from males. Carried ... focuses on the Trinidadian guppy, a species of small freshwater ...
Cached Biology News:Elusive ultrafine indoor air contaminants yield to NIST analysis 2New protocols improve detection of microRNAs for diagnosis 2New protocols improve detection of microRNAs for diagnosis 3Females choose sexier friends to avoid harassment 2
Homo sapiens olfactomedin 1, transcript variant 3...
... Reticulocyte Lysate contains the cellular components necessary ... initiation, elongation and termination factors) but has ... Lysate is used primarily for the isolation ... source of endogenous globin mRNA. Untreated Lysate ...
...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Biology Products: